Weekly Market Wrap
ASX News
Joshua Barker
The ASX 200 fell 34 points or 0.5% to 6177 on Friday, retreating from 7-month highs in the previous session, but closing 1.2% higher for the week. Risk sentiment waned after the IMF panel warned of permanent damage to the economy unless countries are given further economic support.
Consumer confidence soared to its highest level in more than two years on the back of the Morrison government’s big spending Federal Budget. Westpac’s closely watched measure of consumer sentiment jumped by 11.9% in October, with optimists out-numbering pessimists for the first time since 2018. The index has now lifted by 32% over the last two months to the highest level since July 2018.
Top Gainers:
Top Losers:
Wall Street closed mixed on Friday with the Dow rising after three consecutive drops, as economic data surpassed expectations but fiscal uncertainty lingers. Retail sales jumped 1.9% in September and soundly beat consensus estimates of 0.7%, while consumer confidence for October also came in better than expected.
Pfizer said it would apply for emergency use of its Covid-19 vaccine as soon as it reaches safety milestones. For the week, the Dow gained 0.1% and the S&P 0.2%, notching its third straight weekly gain. The Nasdaq added 0.8%, posting a four-week winning streak.
Much of the market’s expectations are based on the timeline of a vaccine being developed and produced to the masses. Global markets have been pricing in for a while now that the US pharma firms would develop a final vaccine and that could at least start being produced by the end of this year.
The recent federal budget, that caused local markets to rally off 5-month lows, makes the key assumption in its models that here in Australia we will have a vaccine dosage to every Australian by the end of 2021. This assumption would have been largely based on the precedent assumption that Australia would have its own vaccine by the middle of next year – as made by the company CSL.
However, with delays in the initial production, this timeline could be pushed back even further. US pharma company Eli Lilly recently paused their trials citing a safety concern. Johnson and Johnson also paused their trails too after a volunteer fell ill. This is the main uncertainty of the markets right now.
Next week, investors’ focus will turn to the final US Presidential Debate between Trump and Biden and third-quarter earnings results with IBM, Netflix and Tesla reporting. Here in Australia, we will see further updates from the RBA by way of the monetary policy.
Weekly Market Wrap
ASX News
Weekly Market Update: 21st of December 2020
ASX UpdateThe market experienced its seventh straight week of gains, adding 0.7% to 6,675 despite dampened sentiment on Friday where the market sold-off throughout the day and closing on the lows. Friday’s losses...
Joshua Barker
Invalid Date
Weekly Market Wrap
Maqro Academy
Stocks
Basics of Fundamental Analysis
Top 5 Fundamental Analysis RatiosFundamental analysis is used to determine a company’s financial health, performance and value for investing purposes. It can be done through studying the firm’s income statement, balance sheet, cash flow statement,...
Miranda B
Apr 20, 2020
Weekly Market Wrap
Volatility Returns on Reopening Economy
Fourth Week of May After markets jumped out of the gates to begin this week on the hope a vaccine was on its way, the ASX200 eyed a -3.5% increase by lunch time Thursday but as...
Joshua Barker
May 25, 2020
Ready to invest with Maqro today?
Sign up to Maqro